US 12,215,162 B2
BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof
Hong Qin, Duarte, CA (US); and Larry W. Kwak, Duarte, CA (US)
Assigned to CITY OF HOPE, Duarte, CA (US); and BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by CITY OF HOPE, Duarte, CA (US); and BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed on Sep. 3, 2021, as Appl. No. 17/466,968.
Application 17/466,968 is a continuation of application No. 16/307,443, granted, now 11,161,908, previously published as PCT/US2017/036178, filed on Jun. 6, 2017.
Claims priority of provisional application 62/396,767, filed on Sep. 19, 2016.
Claims priority of provisional application 62/346,324, filed on Jun. 6, 2016.
Prior Publication US 2022/0010023 A1, Jan. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 37/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 14/73 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 5/16 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 39/3955 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61K 39/464417 (2023.05); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 37/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70514 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/3061 (2013.01); C12N 5/0636 (2013.01); C12N 5/163 (2013.01); A61K 2039/505 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/77 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)] 17 Claims
 
1. A nucleic acid molecule encoding a chimeric antigen receptor, wherein the chimeric antigen receptor comprises an scFv targeted to BAFF-R, wherein the scFv includes a light chain variable region and a heavy chain variable region, wherein the light chain variable region includes CDR L1 (SEQ ID NO:1), CDR L2 (SEQ ID NO:2) and CDR L3 (SEQ ID NO: 3); and the heavy chain variable region includes CDR H1 (SEQ ID NO:4), CDR H2 (SEQ ID NO:5), and CDR H3 (SEQ ID NO:6); a CD4 transmembrane domain or variant thereof having 1-5 amino acid modifications; a costimulatory domain comprising a 4-1BB costimulatory domain or a variant thereof having 1-5 amino acid modifications; and CD3ζ signaling domain or a variant thereof having 1-5 amino acid modifications.